Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.

Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj N.

Cancer Immunol Res. 2020 Jan;8(1):70-80. doi: 10.1158/2326-6066.CIR-19-0545. Epub 2019 Nov 7.

PMID:
31699709
2.

Dendritic Cell Vaccines.

Sabado RL, Meseck M, Bhardwaj N.

Methods Mol Biol. 2016;1403:763-77. doi: 10.1007/978-1-4939-3387-7_44.

PMID:
27076166
3.

Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy.

Eisenstein S, Coakley BA, Briley-Saebo K, Ma G, Chen HM, Meseck M, Ward S, Divino C, Woo S, Chen SH, Pan PY.

Cancer Res. 2013 Aug 15;73(16):5003-15. doi: 10.1158/0008-5472.CAN-12-1597. Epub 2013 Mar 27.

4.

The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer.

Yamaki M, Shinozaki K, Sakaguchi T, Meseck M, Ebert O, Ohdan H, Woo SL.

Int J Mol Med. 2013 Feb;31(2):299-306. doi: 10.3892/ijmm.2012.1205. Epub 2012 Dec 6.

PMID:
23232984
5.

A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer.

Meseck M, Huang T, Ma G, Wang G, Chen SH, Woo SL.

J Immunother. 2011 Mar;34(2):175-82. doi: 10.1097/CJI.0b013e318206dac1.

6.

Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment.

Ausubel LJ, Meseck M, Derecho I, Lopez P, Knoblauch C, McMahon R, Anderson J, Dunphy N, Quezada V, Khan R, Huang P, Dang W, Luo M, Hsu D, Woo SL, Couture L.

Hum Gene Ther. 2011 Apr;22(4):489-97. doi: 10.1089/hum.2010.159. Epub 2011 Mar 8.

7.

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH.

Cancer Res. 2009 Mar 15;69(6):2514-22. doi: 10.1158/0008-5472.CAN-08-4709. Epub 2009 Mar 10.

8.

Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells.

Altomonte J, Wu L, Meseck M, Chen L, Ebert O, Garcia-Sastre A, Fallon J, Mandeli J, Woo SL.

Cancer Gene Ther. 2009 Mar;16(3):266-78. doi: 10.1038/cgt.2008.74. Epub 2008 Oct 10.

9.

rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.

Wu L, Huang TG, Meseck M, Altomonte J, Ebert O, Shinozaki K, García-Sastre A, Fallon J, Mandeli J, Woo SL.

Hum Gene Ther. 2008 Jun;19(6):635-47. doi: 10.1089/hum.2007.163.

10.

FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice.

Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH.

J Clin Invest. 2008 Jun;118(6):2347-64. doi: 10.1172/JCI32914.

11.

Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.

Altomonte J, Wu L, Chen L, Meseck M, Ebert O, García-Sastre A, Fallon J, Woo SL.

Mol Ther. 2008 Jan;16(1):146-53. Epub 2007 Dec 11.

12.

Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation.

Chen L, Huang TG, Meseck M, Mandeli J, Fallon J, Woo SL.

Mol Ther. 2007 Dec;15(12):2194-202. Epub 2007 Oct 30.

13.

Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism.

Qu S, Altomonte J, Perdomo G, He J, Fan Y, Kamagate A, Meseck M, Dong HH.

Endocrinology. 2006 Dec;147(12):5641-52. Epub 2006 Sep 21.

14.

The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.

Xu DP, Sauter BV, Huang TG, Meseck M, Woo SL, Chen SH.

Gene Ther. 2005 Oct;12(20):1526-33.

PMID:
15973445
15.

Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance.

Dong H, Maddux BA, Altomonte J, Meseck M, Accili D, Terkeltaub R, Johnson K, Youngren JF, Goldfine ID.

Diabetes. 2005 Feb;54(2):367-72.

16.

Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.

Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH.

J Clin Invest. 2004 Nov;114(10):1493-503.

17.

Elevated vascular endothelial growth factor production in islets improves islet graft vascularization.

Zhang N, Richter A, Suriawinata J, Harbaran S, Altomonte J, Cong L, Zhang H, Song K, Meseck M, Bromberg J, Dong H.

Diabetes. 2004 Apr;53(4):963-70.

18.

Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice.

Altomonte J, Richter A, Harbaran S, Suriawinata J, Nakae J, Thung SN, Meseck M, Accili D, Dong H.

Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E718-28. Epub 2003 Jun 3.

19.

IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach.

Selleck WA, Canfield SE, Hassen WA, Meseck M, Kuzmin AI, Eisensmith RC, Chen SH, Hall SJ.

Mol Ther. 2003 Feb;7(2):185-92.

20.
21.

Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes.

Morral N, McEvoy R, Dong H, Meseck M, Altomonte J, Thung S, Woo SL.

Hum Gene Ther. 2002 Sep 1;13(13):1561-70.

PMID:
12228011
22.

Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation.

Attur MG, Dave MN, Leung MY, Cipolletta C, Meseck M, Woo SL, Amin AR.

J Immunol. 2002 Feb 15;168(4):2001-10.

23.

Basal insulin gene expression significantly improves conventional insulin therapy in type 1 diabetic rats.

Dong H, Altomonte J, Morral N, Meseck M, Thung SN, Woo SL.

Diabetes. 2002 Jan;51(1):130-8.

24.

Hepatic insulin expression improves glycemic control in type 1 diabetic rats.

Dong H, Morral N, McEvoy R, Meseck M, Thung SN, Woo SL.

Diabetes Res Clin Pract. 2001 Jun;52(3):153-63.

PMID:
11323084
25.

Auto-regulated hepatic insulin gene expression in type 1 diabetic rats.

Chen R, Meseck ML, Woo SL.

Mol Ther. 2001 Apr;3(4):584-90.

26.

Supplemental Content

Loading ...
Support Center